In a report released yesterday, Jack Meehan from Barclays maintained a Buy rating on Laboratory Corp (LH), with a price target of $176. The company’s shares closed yesterday at $152.61.
According to TipRanks.com, Meehan is a 4-star analyst with an average return of 6.9% and a 62.1% success rate. Meehan covers the Healthcare sector, focusing on stocks such as Bio-Rad Laboratories, PRA Health Sciences, and IQVIA Holdings Inc.
Laboratory Corp has an analyst consensus of Moderate Buy, with a price target consensus of $172.30, a 12.9% upside from current levels. In a report issued on April 2, Jefferies also upgraded the stock to Buy with a $190 price target.
See today’s analyst top recommended stocks >>
Laboratory Corp’s market cap is currently $15.09B and has a P/E ratio of 17.73. The company has a Price to Book ratio of 2.17.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Laboratory Corp. of America Holdings is a clinical laboratory company, which engages in the provision of clinical laboratory and end-to-end drug development services. It operates through the LabCorp Diagnostics and Covance Drug Development segments. The LabCorp Diagnostics segment includes core testing as well as genomic and esoteric testing.